Abstract:
Introduction: Recent clinical trials have firmly established that inflammation plays a causal role in human atherosclerosis, the primary driver of cardiovascular diseases (CVDs). Targeting inflammatory pathways, such as interleukin-6 (IL-6), may offer a novel strategy to reduce cardiovascular risk. This study investigates the efficacy of monoclonal antibodies (Mabs) that target IL-6 in reducing inflammatory markers associated with CVD.
Methods: A systematic search was conducted in PubMed, EMBASE, and the Cochrane Library from 1992 to November 2024. Eligible studies included randomized controlled trials (RCTs) or control trials assessing IL-6-targeting Mabs in patients with CVD or high CVD risk. The Cochrane Risk of Bias 2 (RoB 2) tool was used to evaluate methodological quality.
Results: Four RCTs with a total of 5,872 patients were included. All studies reported data on C-reactive protein (CRP), and two reported IL-6 levels. CRP levels were significantly reduced in the Mabs group compared to control (Mean Difference: –3.13 \[–6.15, –0.11], *p* = 0.04), though heterogeneity was high (I² = 95%). IL-6 levels showed a non-significant reduction (SMD: –0.12 \[–0.33, 0.09], *p* = 0.26, I² = 0%). The Mabs used included IL-6 receptor blockers, IL-1β inhibitors, and complement inhibitors.
Conclusion: IL-6-targeting monoclonal antibodies appear to reduce systemic inflammation, particularly CRP levels, in patients with cardiovascular disease. These findings support further investigation into anti-inflammatory strategies for managing atherosclerosis and CVD.
Biography:
To be updated shortly..
Copyright 2024 Mathews International LLC All Rights Reserved
